Fig. 5: Longitudinal measurement of ADA against the AZD5396 and AZD8076 DMAbs. | Nature Medicine

Fig. 5: Longitudinal measurement of ADA against the AZD5396 and AZD8076 DMAbs.

From: Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Fig. 5

a–c, Anti-AZD5396 (left) and anti-AZD8076 (right) ADA measurements are shown for individual participants in the single-dose cohorts (A1/A2) (a), the two-dose cohorts (B–E) (b) and the four-dose cohort (G) (c). The dotted lines represent the assay minimum titer/limit of detection (LOD) of 40 and 80 for the anti-AZD5396 and anti-AZD8076 assays, respectively. aADA levels were only tested up to week 24, not 72 like in other cohorts.

Back to article page